Idera Pharmaceuticals Inc. (NASDAQ: IDRA) is -63.22% lower on its value in year-to-date trading and has touched a low of $1.18 and a high of $6.14 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The IDRA stock was last observed hovering at around $1.32 in the last trading session, with the day’s gains setting it 0.03% off its average median price target of $2.00 for the next 12 months. It is also 85.0% off the consensus price target high of $9.00 offered by 4 analysts, but current levels are -35.0% lower than the price target low of $1.00 for the same period.
Currently trading at $1.35, the stock is -57.39% and -68.95% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 2.17 million and changing 2.27% at the moment leaves the stock -57.74% off its SMA200. IDRA registered 8.00% gain for a year compared to 6-month gain of -40.00%. The firm has a 50-day simple moving average (SMA 50) of $3.7600 and a 200-day simple moving average (SMA200) of $3.7592.
The stock witnessed a -68.09% loss in the last 1 month and extending the period to 3 months gives it a -63.22%, and is -6.25% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 8.28% over the week and 10.30% over the month.
Distance from 52-week low is 14.41% and -78.01% from its 52-week high.
Idera Pharmaceuticals Inc. (IDRA) Analyst Forecasts
Analyst recommendations provided by FactSet shows that the consensus forecast for Idera Pharmaceuticals Inc. (IDRA) is a “Hold”. 4 analysts offering their recommendations for the stock have an average rating of 3.00, where 4 rate it as a Hold and 0 think it is a “Overweight”. 0 of the analysts rate the stock as a “Buy”. 0 analysts have rated the stock as a Sell or Underperform.
Idera Pharmaceuticals Inc. is expected to release its quarterly report on 08/11/2021 and quarterly earnings per share for the current quarter are estimated at -$0.21.The EPS is expected to shrink by -12.50% this year.
Idera Pharmaceuticals Inc. (IDRA) Top Institutional Holders
61 institutions hold shares in Idera Pharmaceuticals Inc. (IDRA), with 11.18M shares held by insiders accounting for 26.45% while institutional investors hold 30.80% of the company’s shares. The shares outstanding are 36.29M, and float is at 25.52M with Short Float at 8.51%. Institutions hold 22.66% of the Float.
The top institutional shareholder in the company is Baker Brothers Advisors, LLC with over 4.61 million shares valued at $16.91 million. The investor’s holdings represent 10.91% of the IDRA Shares outstanding. As of Dec 30, 2020, the second largest holder is Vanguard Group, Inc. (The) with 1.02 million shares valued at $3.75 million to account for 2.42% of the shares outstanding. The other top investors are Renaissance Technologies, LLC which holds 1.01 million shares representing 2.40% and valued at over $3.72 million, while Blackrock Inc. holds 1.43% of the shares totaling 0.6 million with a market value of $2.21 million.
Idera Pharmaceuticals Inc. (IDRA) Insider Activity
A total of 18 insider transactions have happened at Idera Pharmaceuticals Inc. (IDRA) in the last six months, with sales accounting for 11 and purchases happening 7 times. The most recent transaction is an insider sale by Tarka Elizabeth Ann ,the company’sCHIEF MEDICAL OFFICER. SEC filings show that Tarka Elizabeth Ann sold 5,018 shares of the company’s common stock on Mar 25 at a price of $1.35 per share for a total of $6778.0. Following the sale, the insider now owns 13237.0 shares.
Idera Pharmaceuticals Inc. disclosed in a document filed with the SEC on Mar 25 that Lim Bryant David (SVP AND GENERAL COUNSEL) sold a total of 7,630 shares of the company’s common stock. The trade occurred on Mar 25 and was made at $1.36 per share for $10378.0. Following the transaction, the insider now directly holds 30434.0 shares of the IDRA stock.
Still, SEC filings show that on Mar 25, Kirby John J. (CHIEF FINANCIAL OFFICER) disposed off 6,250 shares at an average price of $1.42 for $8876.0. The insider now directly holds 27,632 shares of Idera Pharmaceuticals Inc. (IDRA).